Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Shire CEO Has Big Ophthalmology Plans; SARcode Sets The Stage

This article was originally published in The Pink Sheet Daily

Executive Summary

With its third acquisition this year, Shire gains Phase III Lifitegrast in development for dry eye disease. It expects to launch the product in the U.S. in 2016.

You may also be interested in...

Quick Resubmission Has Shire Seeking Third Quarter Lifitegrast OK

Having produced positive top-line data from a third Phase III trial within two weeks of FDA's complete response letter, Shire made quick work of its reply to the agency on the dry eye disease candidate.

Shire Uses Foresight To Expand In Ophthalmology

Shire acquired Foresight Biotherapeutics for $300 million, gaining a late-stage drug for pink eye that will be a commercial complement to lifitegrast.

Shire Eyes Lifitegrast For Growth But Still Gets Dry Reception

The specialty pharma expressed confidence about the late-stage dry-eye drug lifitegrast at a Dec. 10 R&D day, but analysts remain wary about whether Shire can hit sales goals based on its current pipeline.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts